Kevin Hrusovosky’s career has been dedicated to transforming medicine from reactive “sick care” to preventative personalized care. A serial entrepreneur, he currently serves as the CEO of Quanterix, a company which has just nabbed $700 million and is raising the bar on proteomics testing. “Genomics can tell you what your predisposition is,” he says in today’s interview, “proteomics can tell you the earliest moment you are in a disease cascade.”
Share this post

Will High Sensitivity Proteomics Enable a New Paradigm in Precision Health? with Kevin Hrusovsky, Quanterix
www.mendelspod.com
Mendelspod Podcast
Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine.
Listen on
Substack App
Apple Podcasts
RSS Feed
Will High Sensitivity Proteomics Enable a New Paradigm in Precision Health? with Kevin Hrusovsky, Quanterix